Use of Erythropoietin after solid organ transplantation

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL.8, 2007, Pages

  Schwenger, Vedat ^a   Morath, Christian ^a   Zeier, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endothelial progenitor cells; Erythropoietin; Organ transplantation; Organoprotection

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC DISEASE; CYTOLOGY; ENDOTHELIUM CELL; HEART TRANSPLANTATION; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METABOLISM; METHODOLOGY; ORGAN TRANSPLANTATION; PILOT STUDY; REVIEW; RISK; STEM CELL; TREATMENT OUTCOME;

ANEMIA; CHRONIC DISEASE; ENDOTHELIAL CELLS; ERYTHROPOIETIN, RECOMBINANT; HEART TRANSPLANTATION; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PILOT PROJECTS; RISK; STEM CELLS; TREATMENT OUTCOME;

EID: 42449124251     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm657     Document Type: Conference Paper

References (21)

1. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (Pubitemid 28385655)
2. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084 (Pubitemid 44749316)
3. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
4. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007 (Pubitemid 38056315)
5. Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100: 11612-11617 (Pubitemid 37205984)
6. Jaquet K, Krause K, Tawakol-Khodai M et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64: 326-333
7. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221 (Pubitemid 44427445)
8. El Haggan W, Vallet L, Hurault de Ligny B et al. Darbepoetin alfa in the treatment of anemia in renal transplant patients: a single-center report. Transplantation 2004; 77: 1914-1915 (Pubitemid 38822225)
9. Ortiz F, Guirado L, Diaz J et al. Use of recombinant human erythropoietin in kidney transplant patients with stable graft function. Transplant Proc 2003; 35: 1767-1768 (Pubitemid 37093704)
10. Van Biesen W, Vanholder R, Veys N et al. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367-368 (Pubitemid 40299548)
11. Sharples EJ, Patel N, Brown P et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemiareperfusion. J Am Soc Nephrol 2004; 15: 2115-2124 (Pubitemid 39031350)
12. Felker GM, Gattis WA, Leimberger JD et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92: 625-628 (Pubitemid 37013425)
13. Horwich TB, Fonarow GC, Hamilton MA et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39: 1780-1786 (Pubitemid 34595288)
14. Kosiborod M, Smith GL, Radford MJ et al. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114: 112-119 (Pubitemid 36183592)
15. Sharma R, Francis DP, Pitt B et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004; 25: 1021-1028 (Pubitemid 38869420)
16. Silverberg DS, Wexler D, BlumMet al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-1744 (Pubitemid 30342851)
17. Gleissner CA, Murat A, Schafer S et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 2004; 77: 710-717 (Pubitemid 38366977)
18. Gleissner CA, Klingenberg R, Staritz P et al. Role of erythropoietin in anemia after heart transplantation. Int J Cardiol 2006; 112: 341-347 (Pubitemid 44415051)
19. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-4806 (Pubitemid 36457809)
20. Sepodes B, Maio R, Pinto R et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 2006; 19: 919-926 (Pubitemid 44511117)
21. Guitard J, Ribes D, Kamar N et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. Transplantation 2006; 81: 1525-1531 (Pubitemid 43890889)